J Qian1, S Qin, Z He. 1. Oncology Center, 81 Hospital, PLA, Nanjing 210002, China.
Abstract
OBJECTIVE: To evaluate the effect and toxicity of arsenic trioxide (As2O3) in treating primary liver and gallbladder cancer. METHODS: Twenty-nine advanced primary liver cancer and 4 gallbladder cancer patients were treated with As2O3 injection only, 15 mg i.v. qd for 14-21 days and was repeated after 2 weeks. RESULTS: The overall response rate was 15.2%, 13.8% in primary liver cancer (PR 4, NC 21 and PD 4). It was 25.0% in gallbladder cancer (CR 1, NC 2, PD 1). The major side reactions were mild bone marrow suppression and hepatic functional damage. CONCLUSION: As2O3 injection is effective in treating primary liver and gallbladder cancer with mild side reactions. It is worth studying in the future.
OBJECTIVE: To evaluate the effect and toxicity of arsenic trioxide (As2O3) in treating primary liver and gallbladder cancer. METHODS: Twenty-nine advanced primary liver cancer and 4 gallbladder cancerpatients were treated with As2O3 injection only, 15 mg i.v. qd for 14-21 days and was repeated after 2 weeks. RESULTS: The overall response rate was 15.2%, 13.8% in primary liver cancer (PR 4, NC 21 and PD 4). It was 25.0% in gallbladder cancer (CR 1, NC 2, PD 1). The major side reactions were mild bone marrow suppression and hepatic functional damage. CONCLUSION:As2O3 injection is effective in treating primary liver and gallbladder cancer with mild side reactions. It is worth studying in the future.
Authors: Jennifer Wu; Charles Henderson; Lynn Feun; Peter Van Veldhuizen; Philip Gold; Hui Zheng; Theresa Ryan; Lawrence S Blaszkowsky; Haobin Chen; Max Costa; Barry Rosenzweig; MaryLynn Nierodzik; Howard Hochster; Franco Muggia; Giovanni Abbadessa; Jonathan Lewis; Andrew X Zhu Journal: Invest New Drugs Date: 2009-06-30 Impact factor: 3.850